Only a few have completed phase 3 trials; among these the combination of CDK inhibitors with agents targeting mTOR, BTK, and/or pan-isoform PI3K and mTOR inhibitors along with maintenance rituximab would appear to target MCL in a comprehensive manner. Here, BTK is linked to mantle cell lymphoma.